Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr. Mesa on Investigative Therapies in Myelofibrosis

March 26th 2020

Ruben Mesa, MD, discusses therapiesunder investigation in myelofibrosis.

Dr. Kremyanskaya on MANIFEST Trial With CPI-0610 in Myelofibrosis

March 26th 2020

Marina Kremyanskaya, MD, PhD, discusses the goals of the phase II MANIFEST trial examining the efficacy of CPI-0610 in patients with myelofibrosis.

Dr. Saint Fleur-Lominy on the Use of Ruxolitinib Versus Fedratinib in MPNs

March 25th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the use of ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms.

Mesa Discusses Next Steps in Myelofibrosis

March 25th 2020

Ruben Mesa, MD, discusses the latest advancements in the treatment paradigm for patients with myelofibrosis.

Dr. Cortes on the Utility of Ruxolitinib in MPNs

March 23rd 2020

Jorge E. Cortes, MD, discusses the utility of ruxolitinib in myeloproliferative neoplasms.

Dr. Garcia on Unmet Need in Myelofibrosis

March 23rd 2020

Jacqueline S. Garcia, MD, discusses unmet needs for patients with myelofibrosis who progress on JAK inhibitors.

Dr. Jain on the Role of Allogeneic Transplant in Myelofibrosis

March 23rd 2020

Tania Jain, MBBS, discusses the role of allogeneic stem cell transplant in myelofibrosis.

Dr. Saint Fleur-Lominy on the Role of Transplant in MPNs

March 20th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the role of transplant in myeloproliferative neoplasms.

Dr. Gerds on Design and Safety Analysis of a Trial With Luspatercept in Myelofibrosis

March 19th 2020

Aaron Gerds, MD, assistant professor of medicine in the Hematology and Medical Oncology Department at the Cleveland Clinic Taussig Cancer Institute, discusses the design and safety analysis of a phase II trial of luspatercept in patients with myelofibrosis-associated anemia.

Dr. Saint Fleur-Lominy on Emerging Agents in MPNs

March 19th 2020

Shella Saint Fleur-Lominy, MD, PhD, an assistant professor in the Department of Medicine at NYU Langone Health

Ruxolitinib Combo Shows Potential in Post-MPN AML, But Unmet Need Remains

March 18th 2020

Prithviraj Bose, MD, discusses the high unmet need in post-myeloproliferative neoplasms acute myeloid leukemia and the impact of findings from the phase I/II trial on current and future treatment strategies in the space.

Case Series Shows Feasibility of Haploidentical Transplant in High-Risk Myelofibrosis

March 17th 2020

Haploidentical allogeneic stem cell transplant is a viable treatment option for patients with myelofibrosis who have a higher risk for posttransplant complications and mortality.

Dr. Mesa on the Utility of Fedratinib for Patients With Myelofibrosis Who Progress on Ruxolitinib

March 16th 2020

Ruben Mesa, MD, discusses the utility of fedratinib for patients with myelofibrosis who progress on first-line ruxolitinib.

Dr. Nagalla on the Challenges of Managing Thrombocytopenia in MPNs

March 16th 2020

Srikanth Nagalla, MD, discusses the challenges of managing thrombocytopenia in patients with myeloproliferative neoplasms.

Dr. Saint Fleur-Lominy on Differences Between Ruxolitinib and Fedratinib in MPNs

March 16th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the differences between ruxolitinib and fedratinib in the treatment of patients with myeloproliferative neoplasms.

Multidisciplinary Approach Required for Pulmonary Hypertension in Myelofibrosis

March 16th 2020

Juan C. Lopez-Mattei, MD, FACC, FASE, FSCCT, FSCMR, discusses the findings of the retrospective analysis of pulmonary hypertension in patients with myelofibrosis and their impact on clinical practice.

Dr. Mesa on Challenges With JAK Inhibitors in Myelofibrosis

March 14th 2020

Ruben Mesa, MD, discusses the challenges with using JAK inhibitors in myelofibrosis.

Dr. Garcia on the Managing Thrombocytopenia With Navitoclax in Myelofibrosis

March 10th 2020

Jacqueline S. Garcia, MD, instructor in medicine, Department of Medical Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses the management of thrombocytopenia with navitoclax in patients with myelofibrosis.

Dr. Saint Fleur-Lominy on Impact of Ruxolitinib on Symptom Burden in MPNs

March 5th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the effects ruxolitinib has on symptom burden in patients with myeloproliferative neoplasms.

MPN Research Efforts Expand Beyond JAK1/2 Inhibition, Transplant

March 4th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses some of the current and investigational treatment options for patients with myeloproliferative neoplasms.